

# Ascent Gene Therapy Study

...for CNV Secondary to AMD



## Wet Macular Degeneration

---

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (Ascent)

Principal Investigator:  
Dr. Matthew Ohr

### INCLUSION CRITERIA:

- 50-89 years of age with a clinical diagnosis of CNV secondary to AMD in either eye
- Must have received anti-VEGF therapy before screening visit and demonstrated fluid response
- ETDRS BCVA letter score between 40-78 in study eye at screening visit
- Must be pseudophakic (at least 12 weeks postcataract surgery) in study eye

### EXCLUSION CRITERIA:

- CNV or macular edema in study eye secondary to any causes other than AMD
- Diagnosed with nAMD in study eye more than 4 years from screening visit
- Received gene therapy or previous implant in study eye
- Subfoveal fibrosis or atrophy in the study eye
- Uncontrolled glaucoma with IOP in study eye greater than 23 mmHg

---

Ohio State Department of Ophthalmology & Visual Science • 614-293-5287 • [Research@osumc.edu](mailto:Research@osumc.edu)

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.